X
Pharma Advancement
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
  • Home
  • Articles
  • Drug Development
    • All
    • Clinical Trials
    • FDA Approvals
    • Research & Development
    Avadel Pharmaceuticals Receives

    Avadel Pharmaceuticals Receives Orphan Drug Designation from FDA for LUMRYZ™ (sodium oxybate) for Extended-Release Oral Suspension for the Treatment of Idiopathic Hypersomnia

    Robots and AI in Drug

    Robots and AI in Drug Discovery Are Transforming Medicine

    Stringent Policy around COVID Vaccines Laid by FDA

    Stringent Policy around COVID Vaccines Laid by FDA

    Pharmaceutical-Chemicals Market Booms with Rising API Demand

    Pharmaceutical Chemicals Market Booms with Rising API Demand

    Next in Pharma 2025 Innovations

    Next in Pharma 2025: Innovations Shaping the Future

    Work Smart: Go for Hands-Free Lab Informatics at the Bench, Not Scribbled Notes and Delayed Documentation at Your Desk

    Clinical Development

    AI Revolutionizing Drug Discovery and Clinical Development

    Drug-Development

    China’s Super Me-Too Drug Development: A New Pharma Frontier

    Omics Based Clinical Trials

    Asia Pacific Omics-Based Clinical Trials Market Growth

  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us
No Result
View All Result
Pharma Advancement
No Result
View All Result
Home Drug Development FDA Approvals

EMA Wants To Limit Immune-Regulating Medications Like FDA

Content Team by Content Team
31st October 2022
in FDA Approvals, News
Chinas Institute of Materia Medica Partners With Cyclica on Innovative Drug Repurposing for COVID-19

Note* - All images used are for editorial and illustrative purposes only and may not originate from the original news provider or associated company.

On October 28th, an advisory board to the European Medicines Agency advised restricting the use of a class of medications for inflammatory diseases due to a known association with side effects like cancer and heart attacks.

The group recommended limiting the use of so-called JAK inhibitors to individuals who are at least 65 years of age, are at elevated risk of developing serious heart disease or cancer, or who are current or former smokers. JAK inhibitors should only be administered to these patients if no acceptable therapy alternatives are available, according to the PRAC safety committee of the EMA.

The group also advised against using JAK inhibitors in people with a higher risk of deep vein thrombosis and lung blood clots. The committee recommended that those patients and those at risk for cancer or heart disease be given a lower dose of the medications.

The suggestions, which were submitted to the European Commission for a vote, would apply to the drugs Xeljanz and Cibinqo from Pfizer, Olumiant from Eli Lilly, Rinvoq from AbbVie, and Jyseleca from Galapagos, all of which are sold in Europe.

The committee’s conclusions are the most recent setback for JAK inhibitors, which stop Janus kinases, enzymes linked to inflammation. JAK medications were created to be more practical substitutes for injectable medications like Humira and have been approved for a variety of inflammatory diseases. However, authorities have closely scrutinised safety issues that first surfaced in screening and then in a sizable post-marketing study, resulting in class-wide limits in the U.S. and probably shortly in Europe.

For instance, U.S. regulators severely limited the use of JAK inhibitors in all patients last year, only allowing their use in situations when TNF inhibitors like Humira are ineffective. Although less limited in Europe, the advice will nonetheless have a negative impact on sales forecasts in a significant market. RBC Capital Markets analyst Brian Abrahams observed in a research report from February that the medications have wide uptake across inflammatory indications in Europe.

The EMA’s advice won’t have an impact on the two JAK inhibitors used to cure myelofibrosis, Jakavi by Novartis and Inrebic by Bristol-Myers Squibb. Olumiant’s prospective application to COVID-19, for which it is currently being evaluated in Europe, was not included in the panel’s review either.

The panel stated that the revised recommendations and warnings will be reflected in the package information for each medicine.

Previous Post

China Brings To The Table First COVID Inhaler Vaccination

Next Post

Ancient Viral DNA Guards Against Infections In Human Genome

Related Posts

WuXi Biologics and Virogen Bio partner to advance VG712
News

WuXi Biologics and Virogen Bio partner to advance VG712

19th June 2025
Construction of WuXi Biologics Microbial Manufacturing Site
News

Construction of WuXi Biologics Microbial Manufacturing Site

19th June 2025
Beyfortus From Sanofi to Make Imprint in 2025 26 RSV Season
News

Beyfortus From Sanofi to Make Imprint in 2025-26 RSV Season

19th June 2025
Thermo-Fischer-Accelerator Drug Development an Ideal Choice
News

Thermo Fischer Accelerator Drug Development an Ideal Choice

19th June 2025
IQVIA Custom Built AI Agents for Life Sciences Healthcare
News

IQVIA Custom-Built AI Agents for Life Sciences, Healthcare

19th June 2025
SCHOTT Pharma Invests
News

SCHOTT Pharma Invests EUR 100 Million in RTU Cartridges

9th June 2025
Next Post
DNA

Ancient Viral DNA Guards Against Infections In Human Genome

Qucik Links

  • Drug Development
  • Manufacturing
  • News
  • Events & Conferences
  • Newsletter Archive
Pharma Advancement

About Us

Pharma Advancement is a leading Pharma information centric website. On one side Pharmaadvancement.com has established itself as one of the most efficient and comprehensive source of Pharma information online, dedicated to providing decision makers in all the Pharma industry sectors with reliable, accurate and useful insights into happenings in the Pharma sector.

Subscribe Us

System

  • Search
  • Sitemap
  • RSS Feed

Resources

  • Advertise with us
  • Contact Us
  • Download Mediapack
  • Newsletters Archive

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

No Result
View All Result
  • Home
  • Articles
  • Drug Development
  • Manufacturing
  • Supply Chain
  • Facilities
  • Insights
  • Events
  • Contact Us

© 2017 Copyright © Valuemediaservices 2017 All rights reserved.

Login to your account below

Forgotten Password?

Fill the forms bellow to register

All fields are required. Log In

Retrieve your password

Please enter your username or email address to reset your password.

Log In